Loading [MathJax]/jax/output/HTML-CSS/fonts/TeX/fontdata.js

Journal List > Korean J Nosocomial Infect Control > v.19(2) > 1098345

TOOLS
Phill, Eun, Su, Yeon, Yiel-Hea, and Yoon: Comparison of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Infection Epidemiology
Original Article

J Nosocomial Infect Control 2013;19(2):45-51.

Published online: 3 May 2013

DOI: https://doi.org/10.14192/kjnic.2014.19.2.45

Comparison of Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Infection Epidemiology

Hoon Yoon Phill, Bin Cho Eun, Ji Kim Su, Hee Lee Yeon, Seo Yiel-Hea, Soo Park Yoon

Department of Internal Medicine, Gachon University Gil Hospital, Incheon, Korea

Gachon University Gil Hospital, School of Medicine, Incheon, Korea

Department of Laboratory Medicine, Gachon University Gil Hospital, Incheon, Korea

Address reprint requests to Yoon Soo Park, Department of Internal Medicine, Gachon University, Gil Hospital, 24, Namdongdaero, 774 beon-gil, Namdong-gu, Incheon 405-760, Korea Tel: 032-460-8506, Fax: 032-469-4320 E-mail: yspark@gilhospital.com

Received 2 September 2014       Accepted 20 November 2014

Copyright © 2013, the Korean Thyroid Association. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae are main pathogens of bloodstream infection. We compared the epidemiology of ESBL-producing E. coli and K. pneumoniae.

Methods

From January 2003 through March 2007, we retrospectively investigated the clinical characteristics and comorbidities of patients with bloodstream infection by ESBL-producing E. coli and K. pneumoniae.

Results

During the study period, 79 patients (54 with E. coli and 25 with K. pneumoniae) with blood cultures positive for ESBL-producing E. coli or K. pneumoniae were studied. When comparing the source of bloodstream infections, urinary tract infections (UTIs) were more commonly caused by E. coli (24% vs. 0; P=0.007), and respiratory tract and soft tissue infection (36% vs. 15%; P=0.04, 12% vs. 0; P=0.03, respectively) were more commonly associated with K. pneumoniae. Among hospital-acquired bloodstream infection, third-generation cephalosporin was more commonly used in patients with E. coli than patients with K. pneumoniae (81% vs. 24%, Pä0.001). Medical devices (central venous catheter and urinary catheter) were more commonly used in patients with K. pneumoniae.

Conclusion

ESBL-producing E. coli bloodstream infection is more common in urinary tract infections. ESBL-producing K. pneumoniae is more common in respiratory tract infections and in skin and soft tissue infections. In hospital-acquired infections, ESBL-producing E. coli bloodstream infection is more common in biliary tract infection. ESBL-producing E. coli was more commonly associated with prior frequent antibiotics use and K. pneumoniae was more commonly associated with use of medical devices.

Go to : Goto

Keywords: Bloodstream infection, Epidemiology, ESBL, Escherichia coli, Klebsiella pneumoniae

References

1. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect. 2000; 6:460–3.
2. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005; 18:657–86.
3. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2006; 50:1257–62.
4. Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother. 2006; 50:498–504.
5. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005; 56:52–9.
6. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol. 2004; 42:1089–94.
7. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011; 66:1–14.
crossref
8. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010; 35:316–21.
9. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Perea EJ, Pérez-Cano R, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis. 2006; 42:37–45.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373–83.
crossref
11. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med. 2004; 140:26–32.
12. Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002; 137:791–7.
crossref
13. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect. 2008; 14 Suppl 1:134–43.
14. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med. 2012; 27:128–42.
crossref
15. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010; 23:320–6.
crossref
16. Rossolini GM, D’Andrea MM, Mugnaioli C. The spread of CTX-M-type extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008; 14 Suppl 1:33–41.
17. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010; 65:333–41.
18. Kuster SP, Hasse B, Huebner V, Bansal V, Zbinden R, Ruef C, et al. Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland. Infection. 2010; 38:33–40.
crossref
19. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009; 49:682–90.
20. Park YS, Bae IK, Kim J, Jeong SH, Hwang SS, Seo YH, et al. Risk factors and molecular epidemiology of community-onset extended-spectrum β-lactamase-producing Escherichia coli bacteremia. Yonsei Med J. 2014; 55:467–75.
21. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Cueto MD, Gálvez J. . Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect. 2008; 14:180–3.
22. Kang CI, Kim SH, Kim DM, Park WB, Lee KD, Kim HB, et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004; 25:860–7.
23. Rodríguez-Baño J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. xpert Rev Anti Infect Ther. 2008; 6:671–83.
Go to : Goto

Table 1.
Comparative characteristics of bacteremia due to ESBL producing E. coli and K. pneumoniae
Covariate No. (%) of E. coli bacteremia(N=54) No. (%) of K. pneumoniae bacteremia (N=25) OR (95% CI) P
Type of infection        
Community acquired 12 (22) 2 (8)   0.2
Healthcare associated 11 (20) 6 (24)    
Hospital acquired 31 (57) 17 (68)    
Demographics        
Male 28 (52) 18 (72) 0.42 (0.15-1.17) 0.14
Age (yr, meanSD) 60 18 56 23   0.49
Comorbidity        
Diabetes mellitus 15 (28) 5 (20) 0.65 (0.2-2.05) 0.58
Malignancy 23 (43) 6 (24) 0.43 (0.15-1.23) 0.14
Renal insufficiency 3 (6) 1 (4) 0.71 (0.07-7.17) 1.0
(serum creatinineâ2 mg/dL)        
Dialysis 1 (2) 1 (4) 2.21 (0.13-36.8) 0.54
Heart failure 2 (4) 3 (12) 3.55 (0.55-22.7) 0.32
Chronic liver disease 15 (28) 3 (12) 0.36 (0.09-1.36) 0.16
Cerebrovascular accident 2 (4) 4 (16) 4.95 (0.84-29.1) 0.08
Charlson comorbidity index 3.8 2.5 2.8 2.3   0.1
(meanSD)        
Source of infection        
Primary 8 (15) 7 (28) 2.24 (0.71-7.07) 0.22
Urinary tract 13 (24) 0 (0)   0.007
Biliary tract 21 (39) 4 (16) 0.30 (0.09-0.10) 0.07
Intra-abdominal infection 5 (9) 2 (8) 0.85 (0.15-4.73) 1.0
Liver abscess 1 (2) 2 (8) 4.61 (0.40-53.4) 0.23
Respiratory tract 8 (15) 9 (36) 3.23 (1.07-9.81) 0.04
Skin and soft tissue 0 (0) 3 (12)   0.03
Pitt bacteremia score (meanSD) 2.5 3 3 3.5   0.5
Severe sepsis or septic shock 29 (54) 11 (44) 0.68 (0.26-1.76) 0.47
Mortality        
In hospital mortality 21 (39) 9 (36) 0.88 (0.33-2.36) 1.0
14-day mortality 16 (30) 8 (32) 1.12 (0.40-3.11) 1.0

Abbreviation: ESBL, Extended-spectrum β-lactamase.

Table 2.
Characteristics for hospital acquired bacteremia due to ESBL-producing E. coli and K. pneumoniae
Covariate No. (%) of E. coli bacteremia(N=31) No. (%) of K. pneumoniae bacteremia (N=17) OR (95% CI) P
Demographics        
Male 20 (65) 11 (65) 0.99 (0.29-3.42) 1.00
Age (yr, meanSD) 58 16 52 26   0.32
Comorbidity        
Diabetes mellitus 10 (32) 3 (18) 0.45 (0.1-1.93) 0.33
Malignancy 13 (42) 4 (24) 0.43 (0.11-1.61) 0.34
Renal insufficiency (serum creatinineâ2 mg/dL) 1 (6) 0 (0) 0.94 (0.85-1.03) 0.53
Dialysis 1 (3) 0 (0) 0.97 (0.91-1.03) 1.00
Heart failure 0 (0) 2 (12) 1.13 (0.95-1.35) 0.12
Chronic liver disease 11 (35) 3 (18) 0.39 (0.09-1.66) 0.32
Cerebrovascular accident 1 (3) 2 (12) 4.00 (0.34-47.7) 0.28
Charlson comorbidity index (meanSD) 4.1 2.3 2.9 2.4   0.2
Source of infection        
Primary 6 (19) 6 (35) 2.27 (0.60-8.64) 0.30
Urinary tract 3 (10) 0 (0)   0.54
Biliary tract 15 (48) 1 (6) 0.07 (0.008-0.57) 0.003
Intra-abdominal infection 3 (10) 2 (12) 1.24 (0.18-8.29) 1.00
Liver abscess 0 1 (6)   0.35
Respiratory tract 4 (13) 7 (41) 4.73 (1.13-19.68) 0.036
Skin and soft tissue 0 2 (12)   0.12
Pitt bacteremia score (meanSD) 2.9 3.1 3.6 3.2   0.34
Severe sepsis or septic shock 18 (58) 7 (41) 0.51 (0.15-1.68) 0.37
Previous antimicrobials 3r generation cephalosporin 25 (81) 4 (24)   ä.001
Previous device use        
Central venous catheter 13 (42) 15 (88) 10.39 (2.02-53.4) 0.002
Urinary catheter 8 (26) 13 (77) 9.3 (2.4-37.2) 0.001
Intubation 3 (10) 8 (47) 8.3 (1.8-38.1) 0.009
Mortality        
In hospital mortality 15 (48) 8 (47) 0.95 (0.290-3.10) 1.0
14-day mortality 12 (39) 7 (41) 1.10 (0.33-3.70) 1.0

Abbreviation: ESBL, Extended-spectrum β-lactamase.

TOOLS
Similar articles